Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that develops therapies for glaucoma, corneal disorders, and retinal diseases. Its primary revenue sources come from the sale of its micro-bypass stents, including the iStent, iStent inject, and iStent inject W, which together account for approximately 70% of revenue. The company also generates revenue from its product pipeline, including iStent Infinite and iDose TR, which represent the remaining 30%. Factors supporting the company's endurance include its focus on innovative treatments and a growing market for glaucoma therapies, while potential limitations include competition from other medical device manufacturers and the inherent risks of product development in the pharmaceutical sector.
—
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that develops therapies for glaucoma, corneal disorders, and retinal diseases. Its primary revenue sources come from the sale of its micro-bypass stents, including the iStent, iStent inject, and iStent inject W, which together account for approximately 70% of revenue. The company also generates revenue from its product pipeline, including iStent Infinite and iDose TR, which represent the remaining 30%. Factors supporting the company's endurance include its focus on innovative treatments and a growing market for glaucoma therapies, while potential limitations include competition from other medical device manufacturers and the inherent risks of product development in the pharmaceutical sector.
—
Daily adjusted close
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that develops therapies for glaucoma, corneal disorders, and retinal diseases. Its primary revenue sources come from the sale of its micro-bypass stents, including the iStent, iStent inject, and iStent inject W, which together account for approximately 70% of revenue. The company also generates revenue from its product pipeline, including iStent Infinite and iDose TR, which represent the remaining 30%. Factors supporting the company's endurance include its focus on innovative treatments and a growing market for glaucoma therapies, while potential limitations include competition from other medical device manufacturers and the inherent risks of product development in the pharmaceutical sector.